Cellectis S.A.CLLSNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR-60.4%
5Y CAGR-30.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-60.4%/yr
vs +70.6%/yr prior
5Y CAGR
-30.4%/yr
Recent deceleration
Acceleration
-130.9pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2024 | 3.30% |
| 2023 | -10.11% |
| 2022 | -17.26% |
| 2021 | 52.94% |
| 2020 | -16.29% |
| 2019 | 20.21% |
| 2018 | -3.36% |
| 2017 | 6.25% |
| 2016 | 30.13% |
| 2015 | 227.07% |